284 related articles for article (PubMed ID: 32838499)
21. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
[TBL] [Abstract][Full Text] [Related]
22. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).
Mustafic H; Fayssoil A; Josseran L; Ouadahi M; Grimaldi-Bensouda L; Dubourg O; Annane D; Mansencal N
Am J Cardiol; 2021 May; 147():58-60. PubMed ID: 33617818
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 and ACEI/ARB: Not Associated?
Hajra A; Bandyopadhyay D
Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
[No Abstract] [Full Text] [Related]
24. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Li J; Wang X; Chen J; Zhang H; Deng A
JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
[TBL] [Abstract][Full Text] [Related]
25. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
[TBL] [Abstract][Full Text] [Related]
26. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
[TBL] [Abstract][Full Text] [Related]
27. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
Oussalah A; Gleye S; Clerc Urmes I; Laugel E; Callet J; Barbé F; Orlowski S; Malaplate C; Aimone-Gastin I; Caillierez BM; Merten M; Jeannesson E; Kormann R; Olivier JL; Rodriguez-Guéant RM; Namour F; Bevilacqua S; Losser MR; Levy B; Kimmoun A; Gibot S; Thilly N; Frimat L; Schvoerer E; Guéant JL
Clin Infect Dis; 2020 Dec; 71(9):2447-2456. PubMed ID: 32623470
[TBL] [Abstract][Full Text] [Related]
28. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
Sadria M; Layton AT
PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
[TBL] [Abstract][Full Text] [Related]
29. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Guo J; Huang Z; Lin L; Lv J
J Am Heart Assoc; 2020 Apr; 9(7):e016219. PubMed ID: 32233755
[No Abstract] [Full Text] [Related]
30. Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients.
Wang W; Zhao X; Wei W; Fan W; Gao K; He S; Zhuang X
BMC Infect Dis; 2021 Jan; 21(1):114. PubMed ID: 33494713
[TBL] [Abstract][Full Text] [Related]
31. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
[No Abstract] [Full Text] [Related]
32. Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients.
Baslilar S; Saylan B
Ann Saudi Med; 2021; 41(5):268-273. PubMed ID: 34618609
[TBL] [Abstract][Full Text] [Related]
33. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
[TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
Meng J; Xiao G; Zhang J; He X; Ou M; Bi J; Yang R; Di W; Wang Z; Li Z; Gao H; Liu L; Zhang G
Emerg Microbes Infect; 2020 Dec; 9(1):757-760. PubMed ID: 32228222
[TBL] [Abstract][Full Text] [Related]
35. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
36. Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.
Feng B; Zhang D; Wang Q; Yu F; Zou Q; Xie G; Wang R; Yang X; Chen W; Lou B; Zheng S; Chen Y
J Zhejiang Univ Sci B; 2021 Apr; 22(4):330-340. PubMed ID: 33835767
[TBL] [Abstract][Full Text] [Related]
37. Baseline use of angiotensin-converting enzyme inhibitor/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients.
Shah P; Owens J; Franklin J; Jani Y; Kumar A; Doshi R
J Hypertens; 2020 Dec; 38(12):2537-2541. PubMed ID: 32740406
[TBL] [Abstract][Full Text] [Related]
38. Response to "COVID-19 and ACEI/ARB: Not Associated?".
Schiffrin EL; Flack JM; Ito S; Muntner P; Webb RC
Am J Hypertens; 2020 Aug; 33(8):789-790. PubMed ID: 32415836
[No Abstract] [Full Text] [Related]
39. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
[TBL] [Abstract][Full Text] [Related]
40. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication.
Chen Y; Yang D; Cheng B; Chen J; Peng A; Yang C; Liu C; Xiong M; Deng A; Zhang Y; Zheng L; Huang K
Diabetes Care; 2020 Jul; 43(7):1399-1407. PubMed ID: 32409498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
